Meeting
2022 ASCO Genitourinary Cancers Symposium
Bacteria-specific CXCL13-producing follicular helper T cells are putative prognostic markers to neoadjuvant PD-1 blockade in muscle-invasive urothelial carcinoma.
Authors
Anne-Gaëlle Goubet
Gustave Roussy Cancer Campus, University of Paris Descartes, Villejuif, France
Anne-Gaëlle Goubet , Carolina Alves Costa Silva , Leonardo Lordello De Melo , Marianne Gazzano , Cédric Lebacle , Constance Thibault , Geraldine Pignot , Carole Helissey , Morgan Roupret , Evanguelos Xylinas , Caroline Flament , Virginie Marty , Nicolas Signolle , Baptiste Archambaud , Shayma Bel-Hechmi , Romain Daillere , Gwénaël Le Teuff , Jean-Yves Scoazec , Laurence Zitvogel , Yohann Loriot
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Clinical Trial Registration Number
NCT03212651
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 535)
DOI
10.1200/JCO.2022.40.6_suppl.535
Abstract #
535
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I/Ib study of pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Updated results.
First Author: Andreas Nicholas Saltos
Poster
2024 ASCO Annual Meeting
eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.
First Author: Melissa Lynne Johnson
Poster
2024 ASCO Annual Meeting
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.
First Author: Ghassan K. Abou-Alfa
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu